McKesson plans a $2.25 billion acquisition of Precision Medicine Group to bolster its oncology footprint following a strong first quarter marked by double-digit profit growth and increased shareholder returns.
McKesson is demonstrating strong momentum through a combination of robust organic growth in its Oncology and Multi-Specialty segments and strategic inorganic expansion. The planned $2.25 billion acquisition of Precision Medicine Group is set to bolster its biopharma services and clinical-trial capabilities, while a $5 billion capital return program underscores management's confidence in long-term cash flow generation.
The acquisition aims to expand McKesson's footprint in oncology and biopharma services by adding clinical-trial, CRO, payer-strategy, and market-access capabilities.
While the IRA has created revenue headwinds, McKesson has largely mitigated bottom-line impact because 95% of its contracts are fee-for-service arrangements.
The business has been rebranded as Wellverse, and McKesson is targeting a separation in the second half of next calendar year via a split-off or spin-off.
McKesson Corporation reported robust first-quarter results, highlighted by a 33% revenue surge in its Oncology and Multi-Specialty segment. To further capitalize on this growth, the company announced a $2.25 billion acquisition of Precision Medicine Group. Management also reaffirmed its commitment to shareholders, planning to return $5 billion this year through aggressive buybacks and a 15% dividend hike.
The acquisition is designed to expand McKesson's capabilities in oncology and biopharma services, specifically adding clinical-trial, payer-strategy, and market-access expertise to its existing portfolio.